메뉴 건너뛰기




Volumn 9, Issue 12, 2014, Pages

A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients

Author keywords

[No Author keywords available]

Indexed keywords

CD109 ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CLAUDIN 5; LEUKOCYTE ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; CD109 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR PROTEIN;

EID: 84918593064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114713     Document Type: Article
Times cited : (19)

References (44)
  • 1
    • 0036780251 scopus 로고    scopus 로고
    • Clinical translation of angiogenesis inhibitors
    • Review
    • Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2(10): 727-739. Review.
    • (2002) Nat Rev Cancer , vol.2 , Issue.10 , pp. 727-739
    • Kerbel, R.1    Folkman, J.2
  • 2
    • 30744449235 scopus 로고    scopus 로고
    • Angiogenesis as a therapeutic target
    • 15
    • Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature.15;438(7070):967-974.
    • (2005) Nature , vol.438 , Issue.7070 , pp. 967-974
    • Ferrara, N.1    Kerbel, R.S.2
  • 3
    • 43249095919 scopus 로고    scopus 로고
    • Tumor angiogenesis
    • 8
    • Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 8;358(19):2039-2049.
    • (2008) N Engl J Med , vol.358 , Issue.19 , pp. 2039-2049
    • Kerbel, R.S.1
  • 4
    • 2442621619 scopus 로고    scopus 로고
    • Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    • Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
    • (2004) Nat Rev Drug Discov , vol.3 , pp. 391-400
    • Ferrara, N.1    Hillan, K.J.2    Gerber, H.P.3    Novotny, W.4
  • 5
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl Med 350: 2335-2340.
    • (2004) N Engl Med , vol.350 , pp. 2335-2340
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny3    Cartwright, T.4    Hainsworth, J.5
  • 6
    • 35548947467 scopus 로고    scopus 로고
    • Inhibition of angiogenesis in the treatment of non-small cell lung cancer
    • Keedy VL, Sandler AB (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98(12):1825-1830.
    • (2007) Cancer Sci , vol.98 , Issue.12 , pp. 1825-1830
    • Keedy, V.L.1    Sandler, A.B.2
  • 7
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24.
    • (2006) J Clin Oncol , vol.24 , Issue.1 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3    Hudes, G.R.4    Wilding, G.5
  • 9
    • 27644436870 scopus 로고    scopus 로고
    • Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
    • Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, et al. (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106: 3058-3061.
    • (2005) Blood , vol.106 , pp. 3058-3061
    • Shaked, Y.1    Emmenegger, U.2    Man, S.3    Cervi, D.4    Bertolini, F.5
  • 10
    • 0041589524 scopus 로고    scopus 로고
    • Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
    • Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, et al. (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346.
    • (2003) Cancer Res , vol.63 , pp. 4342-4346
    • Bertolini, F.1    Paul, S.2    Mancuso, P.3    Monestiroli, S.4    Gobbi, A.5
  • 11
    • 33344459620 scopus 로고    scopus 로고
    • Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
    • Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, et al. (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94: 524-531.
    • (2006) Br J Cancer , vol.94 , pp. 524-531
    • Fürstenberger, G.1    Von Moos, R.2    Lucas, R.3    Thürlimann, B.4    Senn, H.J.5
  • 13
    • 33746720071 scopus 로고    scopus 로고
    • Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison
    • Goon PK, Boos CJ, Stonelake PS, Blann AD, Lip GY (2006) Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison. Thromb Haemost 96: 45-52.
    • (2006) Thromb Haemost , vol.96 , pp. 45-52
    • Goon, P.K.1    Boos, C.J.2    Stonelake, P.S.3    Blann, A.D.4    Lip, G.Y.5
  • 14
    • 58849156504 scopus 로고    scopus 로고
    • Validation of a standardized method for enumerating circulating endothelial cells and progenitors: Flow cytometry and molecular and ultrastructural analyses
    • Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, et al. (2009) Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 5 (1): 267-273.
    • (2009) Clin Cancer Res , vol.5 , Issue.1 , pp. 267-273
    • Mancuso, P.1    Antoniotti, P.2    Quarna, J.3    Calleri, A.4    Rabascio, C.5
  • 15
    • 33745939679 scopus 로고    scopus 로고
    • Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
    • 15
    • Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, et al. (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 15;108(2): 452-459.
    • (2006) Blood , vol.108 , Issue.2 , pp. 452-459
    • Mancuso, P.1    Colleoni, M.2    Calleri, A.3    Orlando, L.4    Maisonneuve, P.5
  • 16
    • 0942277099 scopus 로고    scopus 로고
    • Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
    • Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, et al. (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15(1): 139-145.
    • (2004) Ann Oncol , vol.15 , Issue.1 , pp. 139-145
    • Beerepoot, L.V.1    Mehra, N.2    Vermaat, J.S.3    Zonnenberg, B.A.4    Gebbink, M.F.5
  • 17
    • 84867514583 scopus 로고    scopus 로고
    • Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer
    • 2012
    • Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, et al. (2012) Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One. 2012;7(10): e47365.
    • (2012) PLoS One. , vol.7 , Issue.10 , pp. e47365
    • Fleitas, T.1    Martínez-Sales, V.2    Vila, V.3    Reganon, E.4    Mesado, D.5
  • 18
    • 65649091778 scopus 로고    scopus 로고
    • Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel
    • Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, et al. (2009) Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 4(2): 208-213.
    • (2009) J Thorac Oncol , vol.4 , Issue.2 , pp. 208-213
    • Kawaishi, M.1    Fujiwara, Y.2    Fukui, T.3    Kato, T.4    Yamada, K.5
  • 19
    • 84869091543 scopus 로고    scopus 로고
    • Endothelial cell heterogeneity
    • Aird WC (2012) Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2(1):a006429. doi: 10.1101/cshperspect.a006429
    • (2012) Cold Spring Harb Perspect Med , vol.2 , Issue.1 , pp. a006429
    • Aird, W.C.1
  • 20
    • 0030855630 scopus 로고    scopus 로고
    • Heterogeneity of endothelial cells. Specific markers
    • Garlanda C, Dejana E (1997) Heterogeneity of endothelial cells. Specific markers Arterioscler Thromb Vasc Biol 17: 1193-1202.
    • (1997) Arterioscler Thromb Vasc Biol , vol.17 , pp. 1193-1202
    • Garlanda, C.1    Dejana, E.2
  • 21
    • 57749184341 scopus 로고    scopus 로고
    • Molecular heterogeneity of tumor endothelium
    • Aird WC (2009) Molecular heterogeneity of tumor endothelium. Cell Tissue Res 335(1): 271-281.
    • (2009) Cell Tissue Res , vol.335 , Issue.1 , pp. 271-281
    • Aird, W.C.1
  • 22
    • 0032528192 scopus 로고    scopus 로고
    • Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display
    • Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, et al. (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102: 430-437.
    • (1998) J Clin Invest , vol.102 , pp. 430-437
    • Rajotte, D.1    Arap, W.2    Hagedorn, M.3    Koivunen, E.4    Pasqualini, R.5
  • 24
    • 34249822498 scopus 로고    scopus 로고
    • Genes that distinguish physiological and pathological angiogenesis
    • Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, et al. (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11(6): 539-554.
    • (2007) Cancer Cell , vol.11 , Issue.6 , pp. 539-554
    • Seaman, S.1    Stevens, J.2    Yang, M.Y.3    Logsdon, D.4    Graff-Cherry, C.5
  • 26
    • 84860460269 scopus 로고    scopus 로고
    • A new approach for rapid and reliable enumeration of circulating endothelial cells in patients
    • Kraan J, Strijbos MH, Sieuwerts AM, Foekens JA, den Bakker MA, et al. (2012) A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost 10(5): 931-939.
    • (2012) J Thromb Haemost , vol.10 , Issue.5 , pp. 931-939
    • Kraan, J.1    Strijbos, M.H.2    Sieuwerts, A.M.3    Foekens, J.A.4    Den Bakker, M.A.5
  • 27
    • 0036493793 scopus 로고    scopus 로고
    • Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins
    • Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, et al. (2002) Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99: 1683-1691.
    • (2002) Blood , vol.99 , pp. 1683-1691
    • Lin, M.1    Sutherland, D.R.2    Horsfall, W.3    Totty, N.4    Yeo, E.5
  • 28
    • 33845631481 scopus 로고    scopus 로고
    • Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes
    • Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, et al. (2006) Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB 20: 1525-1527.
    • (2006) FASEB , vol.20 , pp. 1525-1527
    • Finnson, K.W.1    Tam, B.Y.2    Liu, K.3    Marcoux, A.4    Lepage, P.5
  • 29
    • 0032803285 scopus 로고    scopus 로고
    • CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells
    • Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, et al. (1999) CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Experimental Hematology 27:8 1282-1294.
    • (1999) Experimental Hematology , vol.27 , Issue.8 , pp. 1282-1294
    • Murray, L.J.1    Bruno, E.2    Uchida, N.3    Hoffman, R.4    Nayar, R.5
  • 30
    • 0025962618 scopus 로고
    • Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets
    • Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, et al. (1991) Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood 77(1) 84-93.
    • (1991) Blood , vol.77 , Issue.1 , pp. 84-93
    • Sutherland, D.R.1    Yeo, E.2    Ryan, A.3    Mills, G.B.4    Bailey, D.5
  • 31
    • 0030695224 scopus 로고    scopus 로고
    • Immunologic phenotype of cultured endothelial cells: Quantitative analysis of cell surface molecules
    • Mutin M, Dignat-George F, Sampol J (1997) Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens 50(5): 449-458.
    • (1997) Tissue Antigens , vol.50 , Issue.5 , pp. 449-458
    • Mutin, M.1    Dignat-George, F.2    Sampol, J.3
  • 32
    • 7244242362 scopus 로고    scopus 로고
    • Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood
    • Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, et al. (2004) Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104(9): 2752-2760.
    • (2004) Blood , vol.104 , Issue.9 , pp. 2752-2760
    • Ingram, D.A.1    Mead, L.E.2    Tanaka, H.3    Meade, V.4    Fenoglio, A.5
  • 33
    • 84864420793 scopus 로고    scopus 로고
    • Genome-wide identification of endothelial cell-enriched genes in the mouse embryo
    • Takase H, Matsumoto K, Yamadera R, Kubota Y, Otsu A, et al. (2012) Genome-wide identification of endothelial cell-enriched genes in the mouse embryo. Blood 120(4): 914-923.
    • (2012) Blood , vol.120 , Issue.4 , pp. 914-923
    • Takase, H.1    Matsumoto, K.2    Yamadera, R.3    Kubota, Y.4    Otsu, A.5
  • 34
    • 0141810332 scopus 로고    scopus 로고
    • Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples
    • van der Pol MA, Broxterman HJ, Westra G, Ossenkoppele GJ, Schuurhuis GJ (2003) Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry B Clin Cytom 55(1): 14-21.
    • (2003) Cytometry B Clin Cytom , vol.55 , Issue.1 , pp. 14-21
    • Van Der Pol, M.A.1    Broxterman, H.J.2    Westra, G.3    Ossenkoppele, G.J.4    Schuurhuis, G.J.5
  • 35
    • 33846798106 scopus 로고    scopus 로고
    • Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms
    • Aird WC (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100(2):158-173.
    • (2007) Circ Res , vol.100 , Issue.2 , pp. 158-173
    • Aird, W.C.1
  • 36
    • 54449099774 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    • 20
    • Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, et al. (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 20;26(30): 4899-4905.
    • (2008) J Clin Oncol , vol.26 , Issue.30 , pp. 4899-4905
    • Dellapasqua, S.1    Bertolini, F.2    Bagnardi, V.3    Campagnoli, E.4    Scarano, E.5
  • 37
    • 73349127099 scopus 로고    scopus 로고
    • Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
    • Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, et al. (2009) Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res 15(24): 7652-7657.
    • (2009) Clin Cancer Res , vol.15 , Issue.24 , pp. 7652-7657
    • Calleri, A.1    Bono, A.2    Bagnardi, V.3    Quarna, J.4    Mancuso, P.5
  • 38
    • 33750286135 scopus 로고    scopus 로고
    • The multifaceted circulating endothelial cell in cancer: Towards marker and target identification
    • Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6(11):835-845.
    • (2006) Nat Rev Cancer , vol.6 , Issue.11 , pp. 835-845
    • Bertolini, F.1    Shaked, Y.2    Mancuso, P.3    Kerbel, R.S.4
  • 39
    • 33846149645 scopus 로고    scopus 로고
    • AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1): 83-95.
    • (2007) Cancer Cell , vol.11 , Issue.1 , pp. 83-95
    • Batchelor, T.T.1    Sorensen, A.G.2    Di Tomaso, E.3    Zhang, W.T.4    Duda, D.G.5
  • 40
    • 84884194253 scopus 로고    scopus 로고
    • Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan
    • 12; eCollection 2013
    • Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, et al. (2013) Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One 12;8(9): e74345 doi: 10.1371/journal.pone.0074345. eCollection 2013.
    • (2013) PLoS One , vol.8 , Issue.9 , pp. e74345
    • Cuppini, L.1    Calleri, A.2    Bruzzone, M.G.3    Prodi, E.4    Anghileri, E.5
  • 41
    • 84901273142 scopus 로고    scopus 로고
    • Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy
    • Mehran R1, Nilsson M, Khajavi M, Du Z, Cascone T, et al. (2014) Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy Cancer Res. DOI: 10.1158/0008-5472.CAN-13-2044
    • (2014) Cancer Res
    • Mehran, R.1    Nilsson, M.2    Khajavi, M.3    Du, Z.4    Cascone, T.5
  • 42
    • 84863012047 scopus 로고    scopus 로고
    • TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types
    • Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, et al. (2012) TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21(2): 212-226.
    • (2012) Cancer Cell , vol.21 , Issue.2 , pp. 212-226
    • Chaudhary, A.1    Hilton, M.B.2    Seaman, S.3    Haines, D.C.4    Stevenson, S.5
  • 43
    • 68049120477 scopus 로고    scopus 로고
    • Host-derived tumor endothelial marker 8 promotes the growth of melanoma
    • Cullen M, Seaman S, Chaudhary A, Yang MY, Hilton MB, et al. (2009) Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res 69(15): 6021-6026.
    • (2009) Cancer Res , vol.69 , Issue.15 , pp. 6021-6026
    • Cullen, M.1    Seaman, S.2    Chaudhary, A.3    Yang, M.Y.4    Hilton, M.B.5
  • 44
    • 0035254206 scopus 로고    scopus 로고
    • CD13/APN is activated by angiogenic signals and is essential for capillary tube formation
    • Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, et al. (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97: 652-659
    • (2001) Blood , vol.97 , pp. 652-659
    • Bhagwat, S.V.1    Lahdenranta, J.2    Giordano, R.3    Arap, W.4    Pasqualini, R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.